What Tesofensine actually is

Tesofensine is a triple monoamine reuptake inhibitor — it blocks reuptake of serotonin, noradrenaline, and dopamine. Originally developed for Parkinson’s and Alzheimer’s disease (where efficacy was insufficient), it produced striking weight-loss signals as a side effect, leading to dedicated obesity trials.¹

In a phase 2b study, tesofensine produced mean weight losses of 6.5–12.8% at 24 weeks across dose levels — substantially larger than orlistat or sibutramine.² Development as an obesity therapy stalled at the time, but interest has revived as physicians look for non-incretin alternatives.

At Luxbae, Tesofensine is prescribed and supervised by Dr. Ernst von Schwarz, MD, PhD after a complimentary medical consultation.

Mechanism — Triple reuptake inhibition

Inhibits serotonin, noradrenaline, and dopamine reuptake — affects appetite, satiety, and reward pathways via central monoaminergic signaling.¹

What the research shows

Appetite suppression. Central monoamine effects on hunger and satiety pathways.¹

Non-incretin. Useful alternative for patients with GLP-1 intolerance.

Reward pathway. Dopaminergic effects may help with hedonic eating.

Side effects: Insomnia, dry mouth, constipation, BP elevation, increased heart rate, occasional mood changes.

FDA note: Not FDA-approved for weight loss. Investigational; prescribed under physician supervision with careful monitoring.

Tesofensine FAQ

Is this an amphetamine?
No — different mechanism. Triple reuptake inhibition is distinct from amphetamine-type stimulants.

Why not approved?
Phase 3 development was paused historically; renewed interest may revisit.

References

1. Astrup A, Madsbad S, Breum L, et al. Effect of tesofensine on bodyweight loss, body composition, and quality of life. Lancet. 2008;372(9653):1906-1913.
2. Astrup A, Meier DH, Mikkelsen BO, et al. Weight loss produced by tesofensine in patients with Parkinson’s or Alzheimer’s disease. Obesity. 2008;16(6):1363-1369.
3. Bello NT, Zahner MR. Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity. Curr Opin Investig Drugs. 2009;10(10):1105-1116.